Company intelligence / Profile preview

CB Pharma Acquisition

Cayman Islands

Ownership: Private
Development stage: Other

Overview

CB Pharma Acquisition was a blank check company (SPAC) incorporated in the Cayman Islands, focused on acquiring or merging with companies in the specialty pharma and generic drug sectors. It did not develop its own pipeline, therapeutic programs, modalities, targets, or clinical results, acting solely as an acquisition vehicle. It later changed its name to Origo Acquisition Corp. and is no longer independently active.

Industry: Investors

Beyond the preview

Go deeper on CB Pharma Acquisition.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CB Pharma Acquisition.

Explore the full profile